But TIGIT has not lived up to the hype, at least not yet. The most recent setback occurred just last week, when Roche reported the failure of its anti-TIGIT antibody in a Phase 3 study involving ...

When added to GSK’s drug Jemperli, the immunotherapy, known as belrestotug and aimed at a cellular target called TIGIT, didn’t meet preset criteria for progression-free survival compared to ...

The study also included a pre-clinical component where a mouse model of human NHL was used to assess the potential impact of TIGIT blockade. The researchers found that blocking TIGIT, in combination ...

While TIGIT was once hyped as the next great immunotherapy target, a number of failed trials has cooled that sentiment, and some drugmakers have pared their TIGIT programs.

Just two weeks after dropping a TIGIT candidate jointly developed with GSK, iTeos has announced plans to wind down operations and explore strategic alternatives. The first half of this year has ...

Like PD-L1, TIGIT is an immune checkpoint that acts as a “brake” to stop T cells from attacking tumors. They work in parallel, so, if you block one, the other will still work, Le said.

ITOS is tantalizing, not sure if TIGIT class lives up to promise, but I believe they have the best shot on goal bc they have the only TIGIT to show mono-therapy activity, and based on the success ...

ARC-7 is a Phase 2, multicenter, three-arm, randomized, open-label study evaluating the combinations of Fc-silent anti-TIGIT monoclonal antibody domvanalimab plus anti-PD1 monoclonal antibody ...

FACS Figure 6. FACS assay shows that Human TIGIT, His Tag (Cat. No. TIT-H52H3) can bind to 293T cell overexpressing human CD155. The concentration of TIGIT used is 0.3 μg/mL. Table 2. Product list.

Gilead and Arcus are evaluating the anti-TIGIT domvanalimab plus zimberelimab in a clutch of phase 3 non-small cell lung cancer (NSCLC) studies. One of those three trials, ARC-10, will see the ...

TIGIT expression can cause T cell exhaustion and NK cell immunosuppression. Thus, it is thought that targeting TIGIT could help reactivate T and NK cells while also suppressing tumor expansion.

BioWorld Content on 'TIGIT'From Roche Holding AG to Novartis AG, bad news abounds for anti-TIGIT immunotherapies. In an SEC filing on July 11, Chinese oncology R&D firm Beigene Ltd. and Basel, ...